PHIO PHARMACEUTICALS CORP (PHIO) Stock Overview
USA - NASDAQ:PHIO - US71880W5013 - Common Stock
PHIO Key Statistics, Chart & Performance
The current stock price of PHIO is 2.06 USD. In the past month the price decreased by -14.67%. In the past year, price decreased by -33.81%.
PHIO Latest News, Press Relases and Analysis
PHIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.61 | 404.23B | ||
| AMGN | AMGEN INC | 13.45 | 157.90B | ||
| GILD | GILEAD SCIENCES INC | 15.44 | 148.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.82 | 107.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.7 | 70.13B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.37B | ||
| ARGX | ARGENX SE - ADR | 87.57 | 49.66B | ||
| INSM | INSMED INC | N/A | 39.69B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5 | 34.11B | ||
| NTRA | NATERA INC | N/A | 27.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.14B | ||
| BIIB | BIOGEN INC | 9.58 | 22.48B |
Related stock screener links
About PHIO
Company Profile
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Company Info
PHIO PHARMACEUTICALS CORP
411 Swedeland Road, Suite 23-1080
King of Prussia PENNSYLVANIA 01752 US
CEO: Gerrit Dispersyn
Employees: 5
Phone: 15087673861
PHIO PHARMACEUTICALS CORP / PHIO FAQ
Can you describe the business of PHIO PHARMACEUTICALS CORP?
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Can you provide the latest stock price for PHIO PHARMACEUTICALS CORP?
The current stock price of PHIO is 2.06 USD. The price decreased by -0.48% in the last trading session.
Does PHIO stock pay dividends?
PHIO does not pay a dividend.
What is the ChartMill rating of PHIO PHARMACEUTICALS CORP stock?
PHIO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for PHIO PHARMACEUTICALS CORP?
PHIO PHARMACEUTICALS CORP (PHIO) currently has 5 employees.
Can you provide the short interest for PHIO stock?
The outstanding short interest for PHIO PHARMACEUTICALS CORP (PHIO) is 5.12% of its float.
PHIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PHIO. When comparing the yearly performance of all stocks, PHIO is a bad performer in the overall market: 89.94% of all stocks are doing better.
PHIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PHIO. No worries on liquidiy or solvency for PHIO as it has an excellent financial health rating, but there are worries on the profitability.
PHIO Financial Highlights
Over the last trailing twelve months PHIO reported a non-GAAP Earnings per Share(EPS) of -6.48. The EPS increased by 83.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.69% | ||
| ROE | -70.18% | ||
| Debt/Equity | 0 |
PHIO Forecast & Estimates
7 analysts have analysed PHIO and the average price target is 14.28 USD. This implies a price increase of 593.2% is expected in the next year compared to the current price of 2.06.